Schedule of Indefinite Lived Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Indefinite-lived Intangible Assets [Line Items]
Net carrying value	$ 607,548	$ 74,430
Talazoparib
Indefinite-lived Intangible Assets [Line Items]
In-process research and development acquired		35,150
Kyndrisa
Indefinite-lived Intangible Assets [Line Items]
In-process research and development acquired	533,064
Other Exons
Indefinite-lived Intangible Assets [Line Items]
In-process research and development acquired	41,044
Reveglucosidase Alfa
Indefinite-lived Intangible Assets [Line Items]
In-process research and development acquired	25,010	25,010
Other Acquired Pre-Clinical Compounds
Indefinite-lived Intangible Assets [Line Items]
In-process research and development acquired	$ 8,430	$ 14,270